Drug intelligence / Profile preview

azurin

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes
Administration
Experimental (likely Intravenous, Intratumoral, Or In Vitro; No Approved Pharmaceutical Route)
01

Overview

Azurin is a bacterial blue-copper protein primarily produced by *Pseudomonas aeruginosa* and other denitrifying bacteria. It functions as a periplasmic electron carrier in bacterial anaerobic respiration and denitrification by transferring electrons between cytochrome c~551~ and nitrite reductase[2]. Structurally, azurin consists of about 128 amino acids forming a stable eight-stranded β-barrel (Greek key motif) with an immunoglobulin-like fold and copper-binding active site[1][2]. Apart from its physiological role, azurin has been investigated for its **anticancer**, **antimicrobial**, **antiparasitic**, and **anti-HIV** properties[1][7]. It induces apoptosis selectively in cancer cells and demonstrates antimicrobial activity by disrupting bacterial membranes[1]. It shows therapeutic promise as a biologic, and a 28-amino acid fragment (p28) derived from azurin has advanced to clinical development for cancer[1].

Other names
bacterial blue-copper proteinBCPPseudomonas aeruginosa azurinP. aeruginosa azurin
02

Targets

EPHB2 (Ephrin type-B receptor 2)TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on azurin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on azurin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call